Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.58 |
| ▸ | GPR183 | P32249 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733606 | 0.91 | HSD11B1 (0.64) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL13789607 | 0.86 | KMT2A (0.60) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL733434 | 0.83 | KMT2A (0.52) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL734913 | 0.81 | CA12 (0.59) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL751828 | 0.80 | ALDH1A1 (0.66) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL755164 | 0.80 | HTT (0.60) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL735124 | 0.79 | LMNA (0.66) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL733985 | 0.79 | HTT (0.62) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL753931 | 0.79 | CNR2 (0.58) | HSD11B1GPR183LMNAGAAMEN1 | |
| SCHEMBL752313 | 0.78 | GPR183 (0.65) | HSD11B1GPR183LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2004619-A1 | 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007111921-A1 | 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111921-A1 | 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | HSD11B1 2477/4885GPR183 2348/4885LMNA 2505/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | HSD11B1 2477/4885GPR183 2348/4885LMNA 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.